These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23712759)

  • 21. Relationship between native-state solubility and non-native aggregation of recombinant human granulocyte colony stimulating factor: practical implications for protein therapeutic development.
    Banks DD; Zhang J; Siska CC
    Mol Pharm; 2014 Oct; 11(10):3431-42. PubMed ID: 25144791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circular dichroism spectroscopy as a tool for monitoring aggregation in monoclonal antibody therapeutics.
    Joshi V; Shivach T; Yadav N; Rathore AS
    Anal Chem; 2014 Dec; 86(23):11606-13. PubMed ID: 25350583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
    Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
    MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability.
    Goldberg DS; Bishop SM; Shah AU; Sathish HA
    J Pharm Sci; 2011 Apr; 100(4):1306-15. PubMed ID: 20960568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies.
    Kayser V; Chennamsetty N; Voynov V; Forrer K; Helk B; Trout BL
    Biotechnol J; 2011 Jan; 6(1):38-44. PubMed ID: 20949542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Descriptor Set for Quantitative Structure-property Relationship Prediction in Biologics.
    Sankar K; Trainor K; Blazer LL; Adams JJ; Sidhu SS; Day T; Meiering E; Maier JKX
    Mol Inform; 2022 Sep; 41(9):e2100240. PubMed ID: 35277930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody therapeutics, antibody engineering, and the merits of protein stability.
    Demarest SJ; Glaser SM
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Therapeutic Antibody Profiler for Computational Developability Assessment.
    Raybould MIJ; Deane CM
    Methods Mol Biol; 2022; 2313():115-125. PubMed ID: 34478133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods.
    Makowski EK; Wu L; Gupta P; Tessier PM
    MAbs; 2021; 13(1):1895540. PubMed ID: 34313532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A GFP-tagged nucleoprotein-based aggregation assay for anti-influenza drug discovery and antibody development.
    Antony H; Schaeffer PM
    Analyst; 2013 Oct; 138(20):6073-80. PubMed ID: 23961535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies.
    Brader ML; Estey T; Bai S; Alston RW; Lucas KK; Lantz S; Landsman P; Maloney KM
    Mol Pharm; 2015 Apr; 12(4):1005-17. PubMed ID: 25687223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction and Reduction of the Aggregation of Monoclonal Antibodies.
    van der Kant R; Karow-Zwick AR; Van Durme J; Blech M; Gallardo R; Seeliger D; Aßfalg K; Baatsen P; Compernolle G; Gils A; Studts JM; Schulz P; Garidel P; Schymkowitz J; Rousseau F
    J Mol Biol; 2017 Apr; 429(8):1244-1261. PubMed ID: 28322916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy.
    Wu J; Schultz JS; Weldon CL; Sule SV; Chai Q; Geng SB; Dickinson CD; Tessier PM
    Protein Eng Des Sel; 2015 Oct; 28(10):403-14. PubMed ID: 26363633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein aggregation kinetics during Protein A chromatography. Case study for an Fc fusion protein.
    Shukla AA; Gupta P; Han X
    J Chromatogr A; 2007 Nov; 1171(1-2):22-8. PubMed ID: 17920607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
    Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining Structural Aggregation Propensity and Stability Predictions To Redesign Protein Solubility.
    Gil-Garcia M; Bañó-Polo M; Varejão N; Jamroz M; Kuriata A; Díaz-Caballero M; Lascorz J; Morel B; Navarro S; Reverter D; Kmiecik S; Ventura S
    Mol Pharm; 2018 Sep; 15(9):3846-3859. PubMed ID: 30036481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a high-throughput solubility screening assay for use in antibody discovery.
    Chai Q; Shih J; Weldon C; Phan S; Jones BE
    MAbs; 2019; 11(4):747-756. PubMed ID: 30913963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions.
    Agrawal NJ; Kumar S; Wang X; Helk B; Singh SK; Trout BL
    J Pharm Sci; 2011 Dec; 100(12):5081-95. PubMed ID: 21789769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging.
    Gerritsen AF; Bosch M; de Weers M; de Winkel JG; Parren PW
    J Immunol Methods; 2010 Jan; 352(1-2):140-6. PubMed ID: 19891971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The uniqueness of flow in probing the aggregation behavior of clinically relevant antibodies.
    Willis LF; Kumar A; Jain T; Caffry I; Xu Y; Radford SE; Kapur N; Vásquez M; Brockwell DJ
    Eng Rep; 2020 May; 2(5):e12147. PubMed ID: 34901768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.